The domestic application and listing of infliximab in Mabo pharmaceutical industry!

Mabo pharmaceutical company announced that it has submitted cmab008 (infliximab) listing application to the State Food and drug administration Cmab008 is a recombinant anti TNF alpha chimeric monoclonal antibody based on infliximab, which is used in the treatment of moderate to severe active rheumatoid arthritis It is the first chimeric anti TNF alpha antibody approved by the State Food and Drug Administration for clinical trials in China by a Chinese native company Compared with infliximab, cmab008 can significantly reduce the immunogenicity The original research of Qiangsheng infliximab (Lek) was approved by the US FDA in 1998 It is the first drug approved by the US FDA and European MEA for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis and Crohn's disease In 2006, it was officially approved in China for the treatment of rheumatoid arthritis, ankylosing spondylitis and Crohn's disease According to the hospital sales data of drug intelligence data, infliximab performed poorly in China's sample hospitals However, with its price of 2006.8 yuan / piece (0.1g, 61% lower than the lowest network price in China) included in the 2019 medical insurance, it can be predicted that it will be a large amount In the case of ensuring clinical benefits, it can also reduce toxic and side effects, which is undoubtedly a good choice for patients, and lay a clinical foundation for domestic alternatives in the future Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.